Cyberonics Shares Up 14% In June, Stimulated By Pending D-04 Trial Results
This article was originally published in The Gray Sheet
Executive Summary
The promise of a concrete regulatory timeline for Cyberonics' NeuroCybernetic Prosthesis vagus nerve stimulation therapy for depression, coupled with a $50 mil. investment by Boston Scientific, drove the firm's stock price up 13.8% in June